Company profile
Esperion Therapeutics, Inc.
NASDAQ: ESPR · Healthcare · Biotechnology
#229 of 1,422 Healthcare companies by revenue68th-percentile growth
EA Score
61CFH 61DQ 55GM 66SS 71
v0.1 · 65/100 weight · provisional
↑ operating margin, 3-yr revenue growth · ↓ balance-sheet leverage, growth stability
Methodology →Revenue TTM
$418.2M
Rev growth YoY (TTM)
+61.1%
Net income (FY)
-$22.7M
Employees
294
as of 2026-08-11
Market cap
$661.1M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$403.1M$403.1M2025
Net income-$22.7M-$22.7M2025
Operating income$60.3M$60.3M2025
Total assets$465.9M$465.9M2025
Liabilities$767.9M$767.9M2025
Equity-$302.0M-$302.0M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Collaboration Revenue60%
Product40%
By geography
Not disclosed.
The read
What is Esperion Therapeutics, Inc.’s revenue?
Esperion Therapeutics, Inc. booked $403.1M in FY2025 revenue, growing 21% year over year — faster than most Healthcare companies we track, at a -5.6% net margin.
Peers · Healthcare
MiMedx Group, Inc.85AInnoviva, Inc.83B+Ardelyx, Inc.68BKrystal Biotech, Inc.77B+Sonida Senior Living, Inc.64CCareDx, Inc78B+Neighbors
Washtenaw →Key facts
CEOSheldon L. Koenig
SectorHealthcare
IndustryBiotechnology
HeadquartersAnn Arbor, MI
ExchangeNASDAQ: ESPR
Employees294
IPO date2013-06-26
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.